Bristol Myers is in a great position both fundamentally and technically. Time horizon is 1-2 years.
Technical:
Ascending Triangle with Price above the 30-day and 210-day simple moving averages. This could squeeze into the previous highs set in 2018 and 2016 (~$75).
We want to see the price continue to stay above these averages as well as the trend line connecting the recent higher lows.
Fundamental:
-Recent Celgene acquisition adds $18B in revenue and diversifies BMY's product portfolio. Before the acquisition, BMY's Top 3 Drugs made up almost 75% of its total revenue. After the acquisition this same ratio is only 43%, decreasing BMY's reliance on its top 3 drugs.
-Last three years the average P/E based on operating earnings for BMY has been 14.21, and at their current price they are trading at a 9.79, suggesting they may be currently undervalued.
-Dividend of $1.92 or 3.14% yield
-21.41% Adjusted Operating Earnings growth rate
-A+ S&P credit rating
Price Target = $100-110
Technical:
Ascending Triangle with Price above the 30-day and 210-day simple moving averages. This could squeeze into the previous highs set in 2018 and 2016 (~$75).
We want to see the price continue to stay above these averages as well as the trend line connecting the recent higher lows.
Fundamental:
-Recent Celgene acquisition adds $18B in revenue and diversifies BMY's product portfolio. Before the acquisition, BMY's Top 3 Drugs made up almost 75% of its total revenue. After the acquisition this same ratio is only 43%, decreasing BMY's reliance on its top 3 drugs.
-Last three years the average P/E based on operating earnings for BMY has been 14.21, and at their current price they are trading at a 9.79, suggesting they may be currently undervalued.
-Dividend of $1.92 or 3.14% yield
-21.41% Adjusted Operating Earnings growth rate
-A+ S&P credit rating
Price Target = $100-110
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.